SK284388B6 - Tableta s riadeným uvoľňovaním alfuzosínhydrochloridu - Google Patents

Tableta s riadeným uvoľňovaním alfuzosínhydrochloridu Download PDF

Info

Publication number
SK284388B6
SK284388B6 SK270-99A SK27099A SK284388B6 SK 284388 B6 SK284388 B6 SK 284388B6 SK 27099 A SK27099 A SK 27099A SK 284388 B6 SK284388 B6 SK 284388B6
Authority
SK
Slovakia
Prior art keywords
layer
tablet according
tablet
layers
granulate
Prior art date
Application number
SK270-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK27099A3 (en
Inventor
Lauretta Maggi
Ubaldo Conte
Pascal Grenier
Guy Vergnault
Alain Dufour
Fran�Ois Xavier Jarreau
Cl�Mence Rauch-Desanti
Original Assignee
Sanofi-Synthelabo
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284388(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9610551A external-priority patent/FR2752737B1/fr
Application filed by Sanofi-Synthelabo, Jagotec Ag filed Critical Sanofi-Synthelabo
Publication of SK27099A3 publication Critical patent/SK27099A3/sk
Publication of SK284388B6 publication Critical patent/SK284388B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK270-99A 1996-08-29 1997-08-22 Tableta s riadeným uvoľňovaním alfuzosínhydrochloridu SK284388B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9610551A FR2752737B1 (fr) 1996-08-29 1996-08-29 Comprime a liberation controlee de chlorhydrate d'alfuzosine
FR9704386 1997-04-10
PCT/FR1997/001515 WO1998008515A1 (fr) 1996-08-29 1997-08-22 Comprime a liberation controlee de chlorhydrate d'alfuzosine

Publications (2)

Publication Number Publication Date
SK27099A3 SK27099A3 (en) 1999-12-10
SK284388B6 true SK284388B6 (sk) 2005-02-04

Family

ID=26232935

Family Applications (1)

Application Number Title Priority Date Filing Date
SK270-99A SK284388B6 (sk) 1996-08-29 1997-08-22 Tableta s riadeným uvoľňovaním alfuzosínhydrochloridu

Country Status (36)

Country Link
US (1) US6149940A (cs)
EP (1) EP0938318B1 (cs)
JP (1) JP3797388B2 (cs)
KR (1) KR100364328B1 (cs)
CN (2) CN100335057C (cs)
AP (1) AP1107A (cs)
AR (1) AR009312A1 (cs)
AT (1) ATE200864T1 (cs)
AU (1) AU724490B2 (cs)
BG (1) BG63768B1 (cs)
BR (1) BR9713237B1 (cs)
CA (1) CA2264250C (cs)
CO (1) CO4920217A1 (cs)
CY (1) CY2284B1 (cs)
CZ (1) CZ295066B6 (cs)
DE (1) DE69704712T2 (cs)
DK (1) DK0938318T3 (cs)
EE (1) EE03855B1 (cs)
ES (1) ES2159400T3 (cs)
GR (1) GR3036291T3 (cs)
HU (1) HU228007B1 (cs)
IL (1) IL128146A (cs)
IS (1) IS2091B (cs)
MX (1) MXPA99001958A (cs)
NO (1) NO326206B1 (cs)
NZ (1) NZ334018A (cs)
OA (1) OA10983A (cs)
PL (1) PL191546B1 (cs)
PT (1) PT938318E (cs)
RU (1) RU2183459C2 (cs)
SI (1) SI0938318T1 (cs)
SK (1) SK284388B6 (cs)
TR (1) TR199900289T2 (cs)
TW (1) TW522023B (cs)
UA (1) UA69374C2 (cs)
WO (1) WO1998008515A1 (cs)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720471B1 (en) 1998-04-28 2004-04-13 The Procter & Gamble Company Absorbent articles having reduced rewet with distribution materials positioned underneath storage material
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
WO2001056544A2 (en) 2000-02-04 2001-08-09 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US7008979B2 (en) 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US6852238B2 (en) * 2002-08-29 2005-02-08 Steller Technology Company Layered tablet water treatment compositions and method of use
US7309444B2 (en) * 2002-08-29 2007-12-18 Stellar Technology Company Layered tablet water treatment compositions and method of use
CA2499550C (en) 2002-09-20 2013-10-15 Alpharma, Inc. Sequestering subunit and related compositions and methods
AU2003278407A1 (en) * 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Sustained release compositions containing alfuzosin
WO2006010640A1 (en) * 2004-07-29 2006-02-02 Sanofi-Aventis Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060062845A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
US20060062846A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
CA2789097C (en) 2005-04-28 2017-02-21 Proteus Digital Health, Inc. Pharma-informatics system
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
CA2912012C (en) 2005-05-05 2018-05-29 Sensient Flavors Inc. Production of beta-glucans and mannans
US20070185235A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070185233A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20090238776A1 (en) * 2005-11-09 2009-09-24 Arif Ali Baig Oral Care Compositions and Methods
US7834066B2 (en) * 2005-11-09 2010-11-16 The Procter & Gamble Company Denture adhesive articles
US20070129460A1 (en) * 2005-11-09 2007-06-07 Jayanth Rajaiah Denture adhesive articles
US20070185236A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070185237A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185232A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US8206742B2 (en) 2006-01-12 2012-06-26 Wockhardt Ltd. Sustained release compositions of alfuzosin
EP3367386A1 (en) 2006-05-02 2018-08-29 Proteus Digital Health, Inc. Patient customized therapeutic regimens
ES2636657T3 (es) 2006-06-19 2017-10-06 Alpharma Pharmaceuticals Llc Composición farmacéutica
US20080003286A1 (en) * 2006-06-29 2008-01-03 Sathya Narayana Vemula Sustained delivery alfuzosin compositions
CA2664641A1 (en) 2006-09-26 2008-04-10 Astellas Pharma, Inc. Controlled release dosage form of tacrolimus
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
MY158019A (en) 2006-10-25 2016-08-30 Proteus Digital Health Inc Controlled activation ingestible identifier
US8718193B2 (en) 2006-11-20 2014-05-06 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US20080138412A1 (en) * 2006-12-06 2008-06-12 Fu-Yung Lin Sustained release alfuzosin hydrochl formulation and method for their production
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
CA2674039A1 (en) 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
PT3785599T (pt) 2007-02-01 2022-10-21 Otsuka Pharma Co Ltd Sistemas de marcadores de eventos ingeríveis
US8956288B2 (en) 2007-02-14 2015-02-17 Proteus Digital Health, Inc. In-body power source having high surface area electrode
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
WO2008112578A1 (en) 2007-03-09 2008-09-18 Proteus Biomedical, Inc. In-body device having a deployable antenna
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US8115618B2 (en) 2007-05-24 2012-02-14 Proteus Biomedical, Inc. RFID antenna for in-body device
EP4011289A1 (en) 2007-09-25 2022-06-15 Otsuka Pharmaceutical Co., Ltd. In-body device with virtual dipole signal amplification
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP3235491B1 (en) 2008-03-05 2020-11-04 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems
BRPI0913398A2 (pt) * 2008-06-04 2015-11-24 Procter & Gamble composição e métodos de adesivo para dentaduras
MY172060A (en) 2008-07-08 2019-11-13 Proteus Digital Health Inc Ingestible event marker data framework
CN102176862B (zh) 2008-08-13 2014-10-22 普罗透斯数字保健公司 可摄入电路
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP3395333A1 (en) 2009-01-06 2018-10-31 Proteus Digital Health, Inc. Pharmaceutical dosages delivery system
CN102341031A (zh) 2009-01-06 2012-02-01 普罗秋斯生物医学公司 摄取相关的生物反馈和个人化医学治疗方法和系统
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
GB2480965B (en) 2009-03-25 2014-10-08 Proteus Digital Health Inc Probablistic pharmacokinetic and pharmacodynamic modeling
EA201190281A1 (ru) 2009-04-28 2012-04-30 Протиус Байомедикал, Инк. Высоконадежные проглатываемые отметчики режима и способы их применения
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
RU2564947C2 (ru) 2010-03-10 2015-10-10 Дзе Проктер Энд Гэмбл Компани Зубопротезные адгезионные композиции
EP2554168B1 (en) 2010-03-29 2018-01-24 Astellas Pharma Inc. Controlled release pharmaceutical composition
JP6463599B2 (ja) 2010-04-07 2019-02-06 プロテウス デジタル ヘルス， インコーポレイテッド 小型の摂取可能なデバイス
MX336038B (es) * 2010-04-07 2016-01-07 Lupin Ltd Composiciones farmaceuticas de liberacion controlada de tapentadol.
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
EP2642983A4 (en) 2010-11-22 2014-03-12 Proteus Digital Health Inc DEVICE INGREABLE WITH PHARMACEUTICAL PRODUCT
CN102475690B (zh) * 2010-11-30 2016-06-01 安国药品株式会社 内含盐酸阿夫唑嗪的缓释片剂
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
EP2734973A4 (en) 2011-07-21 2015-07-01 Proteus Digital Health Inc MOBILE COMMUNICATION DEVICE, SYSTEM AND METHOD
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
WO2014018454A1 (en) 2012-07-23 2014-01-30 Proteus Digital Health, Inc. Techniques for manufacturing ingestible event markers comprising an ingestible component
MY168018A (en) 2012-10-18 2018-10-11 Proteus Biomedical Inc Apparatus, system , and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
JP2016508529A (ja) 2013-01-29 2016-03-22 プロテウス デジタル ヘルス， インコーポレイテッド 高度に膨張可能なポリマーフィルムおよびこれを含む組成物
JP5941240B2 (ja) 2013-03-15 2016-06-29 プロテウス デジタル ヘルス， インコーポレイテッド 金属検出器装置、システム、および方法
EP3005281A4 (en) 2013-06-04 2017-06-28 Proteus Digital Health, Inc. System, apparatus and methods for data collection and assessing outcomes
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
WO2017078557A1 (ru) * 2015-11-05 2017-05-11 Анатолий Викторович ЗАЗУЛЯ Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога
SG10202101937PA (en) 2016-07-22 2021-03-30 Proteus Digital Health Inc Electromagnetic sensing and detection of ingestible event markers
CN109963499B (zh) 2016-10-26 2022-02-25 大冢制药株式会社 用于制造具有可吸收事件标记器的胶囊的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
GB9311191D0 (en) * 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.

Also Published As

Publication number Publication date
HU228007B1 (en) 2012-08-28
CA2264250A1 (en) 1998-03-05
JP2000514462A (ja) 2000-10-31
IS2091B (is) 2006-03-15
CN100335057C (zh) 2007-09-05
AP9901470A0 (en) 1999-03-31
AP1107A (en) 2002-09-20
DK0938318T3 (da) 2001-08-20
PL331862A1 (en) 1999-08-16
HK1020875A1 (en) 2000-05-26
GR3036291T3 (en) 2001-10-31
AR009312A1 (es) 2000-04-12
WO1998008515A1 (fr) 1998-03-05
US6149940A (en) 2000-11-21
KR20000035929A (ko) 2000-06-26
CN1543954A (zh) 2004-11-10
PT938318E (pt) 2001-10-30
MXPA99001958A (es) 2005-09-08
CA2264250C (en) 2005-07-05
JP3797388B2 (ja) 2006-07-19
DE69704712T2 (de) 2001-11-29
OA10983A (fr) 2003-03-04
EP0938318B1 (fr) 2001-05-02
TW522023B (en) 2003-03-01
ATE200864T1 (de) 2001-05-15
BG63768B1 (bg) 2002-12-29
NO326206B1 (no) 2008-10-20
CO4920217A1 (es) 2000-05-29
CN1228700A (zh) 1999-09-15
EE9900090A (et) 1999-10-15
AU4020197A (en) 1998-03-19
SK27099A3 (en) 1999-12-10
EE03855B1 (et) 2002-10-15
BR9713237A (pt) 2000-04-04
NZ334018A (en) 1999-06-29
IS4964A (is) 1999-01-29
CZ295066B6 (cs) 2005-05-18
RU2183459C2 (ru) 2002-06-20
HUP9903428A3 (en) 2000-04-28
IL128146A0 (en) 1999-11-30
SI0938318T1 (en) 2001-12-31
AU724490B2 (en) 2000-09-21
PL191546B1 (pl) 2006-06-30
CN1155382C (zh) 2004-06-30
NO990944L (no) 1999-04-27
DE69704712D1 (de) 2001-06-07
EP0938318A1 (fr) 1999-09-01
NO990944D0 (no) 1999-02-26
ES2159400T3 (es) 2001-10-01
BR9713237B1 (pt) 2009-01-13
CZ65599A3 (cs) 1999-06-16
CY2284B1 (en) 2003-07-04
BG103138A (en) 1999-09-30
TR199900289T2 (xx) 2000-12-21
HUP9903428A2 (hu) 2000-02-28
IL128146A (en) 2001-01-11
KR100364328B1 (ko) 2002-12-26
UA69374C2 (uk) 2004-09-15

Similar Documents

Publication Publication Date Title
SK284388B6 (sk) Tableta s riadeným uvoľňovaním alfuzosínhydrochloridu
EP0795324B1 (en) A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids
US6476006B2 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
KR100618234B1 (ko) 다공성 입자를 포함하는 제형
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
US20060127478A1 (en) Oral dosage formulation
CZ189597A3 (cs) Dávkovací prostředek pro řízené uvolňování suspenze léčiva
CZ303943B6 (cs) Vícevrstvá tableta s rízeným uvolnováním aktivní látky
US20110195120A2 (en) Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride
Majeed et al. Formulation and evaluation of bilayer matrix tablets of amoxicillin and esomeprazole as an oral modified release dosage form for treatment of peptic ulcer
Chowdary et al. Design and evaluation of diltiazem mucoadhesive tablets for oral controlled release
KR20040047920A (ko) 피페라진 우레아 유도체를 위한 고체 제약 제제
US20080220064A1 (en) Extended release matrix formulations of morphine
WO2003084510A1 (en) Novel pharmaceutical compositions for antihistaminic-decongestant combination and method of making such compositions
JPS61221116A (ja) 錠剤の組成物
HK1020875B (en) Tablet with controlled release of alfuzosine chlorydrate

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20170822